Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19598493 | 0.93 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2KCNH2HRH3CHRM2 | |
| SCHEMBL19958953 | 0.89 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2KCNH2HRH3CHRM2 | |
| SCHEMBL22560532 | 0.87 | KCNH2 (0.33) | ALDH1A1SMN1; SMN2KCNH2HRH3CHRM2 | |
| SCHEMBL20437028 | 0.87 | KCNH2 (0.33) | ALDH1A1SMN1; SMN2KCNH2HRH3CHRM2 | |
| SCHEMBL10159897 | 0.87 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2KCNH2HRH3CHRM2 | |
| SCHEMBL824037 | 0.82 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KCNH2HRH3CHRM2 | |
| SCHEMBL19958939 | 0.82 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2KCNH2HRH3CHRM2 | |
| SCHEMBL20317388 | 0.82 | KDM4E (0.36) | ALDH1A1SMN1; SMN2KCNH2HTR1AADRA1A | |
| SCHEMBL21472754 | 0.81 | HRH3 (0.36) | HRH3DRD3 | |
| SCHEMBL29314432 | 0.81 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2KCNH2HRH3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240018149-A1 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | ANHORN MEDICINES CO., LTD. (TW) | 2024-01-18 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210040081-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | ALDH1A1 2833/4885SMN1; SMN2 2113/4885KCNH2 4861/4885 |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | ALDH1A1 3671/4885SMN1; SMN2 1838/4885KCNH2 4867/4885 |
| US-20210040081-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | ALDH1A1 1117/4885SMN1; SMN2 4744/4885KCNH2 3892/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ALDH1A1 2211/4885SMN1; SMN2 1811/4885KCNH2 4850/4885 |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | ALDH1A1 1117/4885SMN1; SMN2 4744/4885KCNH2 3892/4885 |
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ESR1, GPER1, ESR2 | ALDH1A1 1117/4885SMN1; SMN2 4744/4885KCNH2 3892/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | ALDH1A1 3751/4885SMN1; SMN2 2772/4885KCNH2 4873/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | ALDH1A1 2567/4885SMN1; SMN2 269/4885KCNH2 4836/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | ALDH1A1 3688/4885SMN1; SMN2 881/4885KCNH2 4805/4885 |
| US-20240018149-A1 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | MDM2, PSMG3, ADRM1 | ALDH1A1 4137/4885SMN1; SMN2 404/4885KCNH2 4878/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | ALDH1A1 4021/4885SMN1; SMN2 464/4885KCNH2 4712/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | ALDH1A1 3688/4885SMN1; SMN2 881/4885KCNH2 4805/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | ALDH1A1 3671/4885SMN1; SMN2 1838/4885KCNH2 4867/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | ALDH1A1 3412/4885SMN1; SMN2 1348/4885KCNH2 4858/4885 |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | ALDH1A1 3236/4885SMN1; SMN2 1459/4885KCNH2 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.